How have TCBPW shares performed in 2024?

TC Biopharm's stock was trading at $0.0325 at the beginning of the year. Since then, TCBPW stock has decreased by 37.8% and is now trading at $0.0202. View the best growth stocks for 2024 here .

How do I buy shares of TC Biopharm?

Shares of TCBPW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TCBPW

TC Biopharm (TCBPW) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free TCBPW Stock Alerts

$0.02

0.00 (-3.35%)

(As of 12:37 PM ET)

Compare

Today's Range: $0.02
▼
$0.03
50-Day Range: $0.01
▼
$0.04
52-Week Range: $0.00
▼
$0.13

Volume: 13,088 shs
Average Volume: 41,904 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Headlines Short Interest Social Media

Get TC Biopharm alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About TC Biopharm Stock (NASDAQ:TCBPW)

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

TCBPW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TCBPW Stock News Headlines

January 4, 2024 | msn.com

TC BioPharm regains compliance with Nasdaq

January 3, 2024 | marketwatch.com

TC BioPharm Shares Drop After Half of Workforce Gets Cut

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

January 3, 2024 | finance.yahoo.com

TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies

December 19, 2023 | marketwatch.com

TC BioPharm Shares Tumble After Offering Gets Priced

December 13, 2023 | msn.com

TC Biopharm plans to implement ADS ratio change

December 13, 2023 | finance.yahoo.com

TC BioPharm Announces Plan to Implement ADS Ratio Change

November 28, 2023 | msn.com

TC BioPharm receives FDA approval for AML cell therapy trial

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

November 2, 2023 | marketwatch.com

TC BioPharm Inks Trial-Management Deal With Fortrea Amid Cost Cutting

November 2, 2023 | finance.yahoo.com

TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials

October 30, 2023 | morningstar.com

ADRs End Higher; TC Biopharm PLC Climbs 19%

October 25, 2023 | finance.yahoo.com

TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements

October 23, 2023 | markets.businessinsider.com

TC BioPharm Announces Filing Of IND For TCB-008 - Quick Facts

October 23, 2023 | finance.yahoo.com

TC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse/Refractory AML

October 12, 2023 | finance.yahoo.com

TC Biopharm (Holdings) Plc (TCBPW)

September 27, 2023 | finance.yahoo.com

TC BioPharm to Present at the LD Micro Main Event XVI

July 31, 2023 | finance.yahoo.com

TC BioPharm Maintains Nasdaq Listing

July 6, 2023 | finance.yahoo.com

TC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day Podcast

May 24, 2023 | finance.yahoo.com

TC BioPharm to Present at LD Micro Invitational XIII Conference on June 7, 2023

March 30, 2023 | finance.yahoo.com

TC BioPharm Announces Closing of $5.5 Million Public Offering

March 28, 2023 | morningstar.com

ADRs End Higher, Ambev and TC BioPharm Trade Higher

March 28, 2023 | finance.yahoo.com

TC BioPharm Announces Pricing of $5.5 Million Public Offering

March 22, 2023 | markets.businessinsider.com

TC BioPharm Unveils Corporate Restructuring Plan; To Cut Up To 30% Of Workforce

March 22, 2023 | finance.yahoo.com

TC Biopharm Announces Corporate Restructuring, Reduction in Overhead

March 7, 2023 | finance.yahoo.com

TC BioPharm Shifts Focus to FDA Clinical Trials

February 23, 2023 | finance.yahoo.com

TC BioPharm Announces Dr. Mike Leek as Chief Technology Officer

See More Headlines

Receive TCBPW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TC Biopharm and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:TCBPW
CUSIP: N/A
CIK: 1872812
Web: www.tcbiopharm.com
Phone: 44 14 1433 7557
Fax: N/A
Employees: 41
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $2.86 million
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Bryan L. Kobel (Age 45)
CEO & Director
Mr. Martin E. Thorp (Age 72)
CFO & Director
Mr. Christopher Camarra
Executive Vice President of Communications
Dr. Lauren Bor Ph.D.
Head of Commercial Development Division

Key Competitors

View All Competitors

TCBPW Stock Analysis - Frequently Asked Questions

How have TCBPW shares performed in 2024?: TC Biopharm's stock was trading at $0.0325 at the beginning of the year. Since then, TCBPW stock has decreased by 37.8% and is now trading at $0.0202.
View the best growth stocks for 2024 here.
How do I buy shares of TC Biopharm?: Shares of TCBPW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TCBPW) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial